Maven Securities LTD Acquires Shares of 129,700 Vaxcyte, Inc. (NASDAQ:PCVX)

Maven Securities LTD bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 129,700 shares of the company's stock, valued at approximately $14,821,000. Vaxcyte comprises 0.3% of Maven Securities LTD's investment portfolio, making the stock its 8th biggest holding. Maven Securities LTD owned approximately 0.10% of Vaxcyte at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Riverview Trust Co purchased a new stake in Vaxcyte in the third quarter valued at approximately $27,000. Fifth Third Bancorp acquired a new position in shares of Vaxcyte in the second quarter valued at approximately $35,000. Blue Trust Inc. increased its holdings in shares of Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after purchasing an additional 93 shares during the period. J.Safra Asset Management Corp increased its holdings in shares of Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after purchasing an additional 526 shares during the period. Finally, Quest Partners LLC acquired a new position in shares of Vaxcyte in the second quarter valued at approximately $70,000. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Price Performance

PCVX traded up $2.67 during trading on Wednesday, hitting $93.04. The company's stock had a trading volume of 759,375 shares, compared to its average volume of 906,130. The firm's 50 day moving average price is $104.69 and its 200-day moving average price is $90.71. The stock has a market cap of $11.60 billion, a PE ratio of -19.65 and a beta of 0.94. Vaxcyte, Inc. has a twelve month low of $53.26 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same period last year, the company earned ($0.91) EPS. Equities analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Bank of America upped their price objective on Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a report on Wednesday, September 4th. BTIG Research boosted their price target on Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Leerink Partners upped their target price on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research note on Tuesday, September 3rd. Finally, Mizuho upped their target price on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $147.50.

Insider Activity at Vaxcyte

In related news, SVP Mikhail Eydelman sold 5,000 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $109.27, for a total value of $546,350.00. Following the completion of the sale, the senior vice president now directly owns 28,623 shares in the company, valued at approximately $3,127,635.21. This represents a 14.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares of the company's stock, valued at approximately $10,479,005.02. The trade was a 8.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 110,464 shares of company stock worth $11,924,596. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.